0001690080 false 0001690080 2023-01-18 2023-01-18 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2023-01-18 2023-01-18 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2023-01-18 2023-01-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Date of Report (Date of earliest event reported): January 18, 2023



(Exact Name of Registrant as Specified in Charter)


Delaware   001-38105   90-1890354
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, CA

(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (650507-0669


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ATNF   The NASDAQ Stock Market LLC
Warrants to purchase shares of Common Stock   ATNFW   The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 18, 2023, Mr. Quan Vu resigned as Chief Operating/Chief Business Officer of 180 Life Sciences Corp. (the “Company”, “we” and “us”) effective the same date, and entered into a Separation and Release Agreement with the Company (the “Separation Agreement”).


Under the Separation Agreement, the Company agreed to pay Mr. Vu (a) $281,190, less all applicable withholdings and required deductions; and (b) reimburse up to $1,100 a month for eight months for Mr. Vu’s health insurance expenses, whether under COBRA or otherwise (collectively, (a) and (b), the “Severance Payment”). The Severance Payment (except for the amounts payable pursuant to (b) which shall be paid by the 15th day of each calendar month during the applicable eight-month period) is required to be paid within 30 days of the Separation Date (the “Payment Date”). In addition to the Severance Payment, by the Payment Date, the Company agreed to pay Mr. Vu $73,645 for accrued backpay, $16,250 for backpay related to a 2021 bonus, and $36,050 for accrued paid time off. Under the Separation Agreement, Mr. Vu agreed that his resignation was voluntary, provided a customary general release to the Company and also agreed to certain confidentiality, non-disclosure, non-solicitation, non-disparagement, and cooperation covenants in favor of the Company.


The foregoing summary of the Separation Agreement is a summary only and is qualified in its entirety by reference to the Separation Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated into this Item 5.02 by reference in its entirety.


The Company is in the process of determining the best course of action going forward for the potential replacement of its Chief Operating/Chief Business Officer. In the interim, to assist the Company in its ongoing potential out-licensing initiatives and business development activities, the Company will continue to rely on the advice and counsel of various consultants including Dr. Glenn Larsen, co-founder and former CEO and Chairman of 180 Therapeutics, LP, a wholly-owned subsidiary of the Company which houses the Company’s assets for anti-tumor necrosis factor (“TNF”) therapy. Dr. Larsen brings significant experience from his tenure in the discovery, development, partnering and commercialization of pharmaceutical and biotechnology products.


Item 9.01. Exhibits.


(d) Exhibits.


Exhibit No.   Description
10.1*   Separation and Release Agreement, dated January 18, 2023, by and between 180 Life Sciences Corp. and Quan Vu
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)



* Filed herewith.
** Furnished herewith.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 20, 2023 By: /s/ James N. Woody, M.D., Ph.D.
    James N. Woody, M.D., Ph.D.
    Chief Executive Officer